Neoadjuvant chemotherapy offers a pragmatic alternative to the difficulties associated with delivering timely adjuvant chemotherapy in rectal cancer. Enthusiasm for administering neoadjuvant therapy to all patients with locally advanced rectal cancer is based on data from several phase III trials. Data from the RAPIDO trial are a critical component of this evidence.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Bahadoer, R. R. et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open label, phase 3 trial. Lancet Oncol. 22, 29–42 (2021).
Conroy, T. et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 22, 702–715 (2021).
Jin, J. et al. A multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR): the final reports. J. Clin. Oncol. 40, 1681–1692 (2022).
Dijkstra, E. A. et al. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared to long-course chemoradiotherapy and surgery – a five-year follow-up of the RAPIDO Trial. Ann. Surg. https://doi.org/10.1097/SLA.0000000000005799 (2023).
Ciseł, B. et al. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann. Oncol. 30, 1298–1303 (2019).
Liao, C. K. et al. Neoadjuvant short-course radiotherapy followed by consolidation chemotherapy before surgery for treating locally advanced rectal cancer: a systematic review and meta-analysis. Curr Oncol. 29, 3708–3727 (2022).
Lefevre, J. H. et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J. Clin. Oncol. 34, 3773–3780 (2016).
Erlandsson, J., Pettersson, D., Glimelius, B., Holm, T. & Martling, A. Postoperative complications in relation to overall treatment time in patients with rectal cancer receiving neoadjuvant radiotherapy. Br. J. Surg. 106, 1248–1256 (2019).
Deidda, S. et al. Association of delayed surgery with oncologic long-term outcomes in patients with locally advanced rectal cancer not responding to preoperative chemoradiation. JAMA Surg. 156, 1141–1149 (2021).
Jankowski, M. et al. Watch-and-wait strategy in rectal cancer: is there a tumour size limit? Results from two pooled prospective studies. Radiother. Oncol. 160, 229–235 (2021).
R.G.-J. has acted as an advisor and/or consultant of Amgen and Incyte and has received honoraria for lectures from Servier and Johnson & Johnson. J.H. declares no competing interests.
Rights and permissions
About this article
Cite this article
Glynne-Jones, R., Hollingshead, J. TNT and local recurrence in the RAPIDO trial — untangling the puzzle. Nat Rev Clin Oncol 20, 357–358 (2023). https://doi.org/10.1038/s41571-023-00751-4
This article is cited by
Effect of short-course radiotherapy followed by oxaliplatin-based consolidation chemotherapy on organ preservation in locally advanced rectal cancer
International Journal of Colorectal Disease (2023)